Medincell SA
PAR:MEDCL
Medincell SA
MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. The company is headquartered in Jacou, Occitanie and currently employs 150 full-time employees. The company went IPO on 2018-10-08. The firm is focused on the development of therapeutic solutions with worldwide access. The firm works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.
MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. The company is headquartered in Jacou, Occitanie and currently employs 150 full-time employees. The company went IPO on 2018-10-08. The firm is focused on the development of therapeutic solutions with worldwide access. The firm works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.
Olanzapine LAI Filing: MedinCell and partner Teva filed Olanzapine LAI with the FDA, starting a 10-month review period and targeting potential approval by Q4 2025 and launch before end of 2026.
UZEDY Growth: UZEDY long-acting risperidone continues strong growth, with Teva reaffirming 2025 sales guidance of $190–200 million and a 65% increase in Q3 sales year-over-year (USD).
Financials: Revenue rose 50% over the half year, driven by UZEDY royalties and R&D partnerships, while operating expenses increased 22%, and operating loss improved by 13% to EUR 6.6 million.
Pipeline Progress: MedinCell's pipeline is advancing, with AbbVie #1 program set to enter Phase I in 2026, and additional late-stage and early-stage programs underway, several funded by the Gates Foundation.
Strategic Outlook: Management focuses on three growth engines—UZEDY, Olanzapine LAI, and the pipeline—and expects ongoing innovation, global partnerships, and potential new blockbusters.
